Table 2.
Observed |
Standardizeda |
||||||
---|---|---|---|---|---|---|---|
No. Deaths | No. Person-years | 10-year Mortality Risk, % | 10-year Mortality Risk, % | Risk Difference, % (95% CI) | Risk Ratio (95% CI) | Hazard Ratio (95% CI) | |
Overall | 1224 | 51,121.1 | 20.2 | 20.2 | … | … | … |
Race/ethnicity/sex | |||||||
Black women | 207 | 6,730.0 | 25.0 | 25.8 | 7.9 (3.9, 12.0) | 1.44 (1.21, 1.72) | 1.57 (1.32, 1.87) |
Black men | 458 | 13,338.4 | 27.0 | 25.2 | 7.2 (4.3, 10.1) | 1.40 (1.23, 1.61) | 1.53 (1.33, 1.76) |
White men | 405 | 21,792.3 | 16.8 | 18.0 | 0 | 1 | 1 |
Hispanic men | 86 | 5,924.6 | 12.5 | 14.8 | −3.2 (−7.1, .8) | 0.82 (.63, 1.08) | 0.82 (.64, 1.05) |
White women | 53 | 2,482.0 | 17.5 | 13.9 | −4.0 (−8.5, .4) | 0.77 (.57, 1.05) | 0.85 (.61, 1.19) |
Hispanic women | 15 | 853.9 | 12.0 | 10.8 | −7.1 (−16.1, 1.9) | 0.61 (.26, 1.42) | 0.68 (.37, 1.23) |
Race/ethnicity | |||||||
White | 458 | 24,274.3 | 16.9 | 17.2 | 0 | 1 | 1 |
Black | 665 | 20,068.4 | 26.3 | 25.4 | 8.2 (5.6, 10.8) | 1.48 (1.30, 1.67) | 1.29 (1.12, 1.49) |
Hispanic | 101 | 6,778.5 | 12.5 | 14.5 | −2.7 (−6.6, 1.1) | 0.84 (.65, 1.09) | 0.75 (.59, .96) |
Sex | |||||||
Men | 949 | 41,055.3 | 19.7 | 19.8 | 0 | 1 | 1 |
Women | 275 | 10,065.8 | 22.2 | 22.0 | 2.2 (−0.7, 5.2) | 1.11 (.97, 1.28) | 0.95 (.82, 1.10) |
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; No., number.
a Standardized for calendar date of therapy initiation, age at therapy initiation, CD4 cell count (cells/mm3) and HIV-1 RNA plasma concentration (viral load) (log10 copies/mL) most proximate to therapy initiation measured between 6 months prior to 14 days after therapy initiation, antiretroviral therapy naivety (ie, no evidence of prior exposure to mono or dual therapy), prior AIDS diagnosis, history of injection drug use, and history of hepatitis C virus infection; additionally, race/ethnicity risk was standardized for sex and sex risk was standardized for race/ethnicity.